<?xml version="1.0" encoding="UTF-8"?>
<title-group>
 <article-title>Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results</article-title>
 <alt-title alt-title-type="left-running-head">Cortes et al.</alt-title>
</title-group>
